قالب وردپرس درنا توس
Home / Health / Local OBGYN addresses the first FDA-approved postpartum drug

Local OBGYN addresses the first FDA-approved postpartum drug



COLLEGE STATION, Texas (KBTX) – The US Food and Drug Administration (FDA) has launched the first drug to treat symptoms of severe postpartum depression in new mothers.

Zulresso, developed by Sage Therapeutics, is administered by an IV over two and a half days that require a stay at a medical center. The drug is said to mimic natural hormones that are usually lower in a woman after birth

According to clinical studies, the drug works within 48 hours but is quite expensive, averaging $ 34,000 per patient without the two-day drug.

Dr. Nancy Bertsch, an obstetrician at Baylor Scott & White College, believes the drugs target women with severe postpartum depression but are definitely a step in the right direction.

"So for women who are suffering from severe postpartum depression that may not respond to our usual first-line treatments, this could be a good option for them. It offers a new innovation drug, "says Bertsch.

Local doctors say the symptoms of PPD are affecting over four hundred thousand American women a year, and suggest talking to your doctor if you notice symptoms.

Bertsch says that there are many different manifestations of PPD, but some of the most common symptoms are: sad, whiny, anxious, difficult ties with the baby and isolationism.

"I think the more we talk about it, the more we say "Yes, that happens in 1

0% of PPD patients, making it a bit easier to talk and educate about the family and the healthcare provider," says Bertsch

. Sage Therapeutics plans to begin selling the IV drug by the end of June, and is currently in clinical trials with a similar pill treatment.


Source link